ClinicalTrials.Veeva

Menu

A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19

Fudan University logo

Fudan University

Status

Enrolling

Conditions

COVID-19

Treatments

Drug: Paxlovid

Study type

Observational

Funder types

Other

Identifiers

NCT05387369
KY2022-552

Details and patient eligibility

About

The study was designed to analyze the efficacy and safety of Paxlovid for the treatment of COVID-19.

Full description

The study is a real-world study and the case records of patients with COVID-19 who visit Huashan Hospital affiliated to Fudan University from 2022 to 2027 and receive Paxlovid therapy will be collected in this study. The medical data including patient demographic, clinical characteristics, laboratory examination, history of treatments, adverse reactions and treatment outcome will be extracted to analyze the effectivity and safety of paxlovid and explore the prognosis-relevant factors of COVID-19.

Enrollment

2,000 estimated patients

Sex

All

Ages

12+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Participants who have a positive SARS-CoV-2 test result;
  • Participants who have one or more mild or moderate COVID-19 symptoms.

Exclusion criteria

  • No specific exclusion criteria in this real world study.

Trial design

2,000 participants in 2 patient groups

Paxlovid
Description:
Patients with COVID-19 who visit Huashan Hospital,Fudan University from 2022 to 2027 and receive Paxlovid therapy
Treatment:
Drug: Paxlovid
Routine therapy
Description:
Patients with COVID-19 who visit Huashan Hospital,Fudan University from 2022 to 2027 and receive routine therapy without paxlovid

Trial contacts and locations

1

Loading...

Central trial contact

Feng Sun, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems